Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Introduces revolutionary approach to workflow management to enhance operational efficiency and optimize process efficiency
Overall investment in the US facility is estimated around US$50 million
This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
We now rank 3rd in pharmaceutical production by volume and 14th by value
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Subscribe To Our Newsletter & Stay Updated
